{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:01:13Z","timestamp":1790834473817,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) require a balance between maintaining circuit patency and minimizing bleeding risk. Nafamostat mesilate (NM) is a short-acting anticoagulant with distinctive pharmacokinetic properties, including rapid metabolism and a short half-life, which may reduce prolonged systemic anticoagulant exposure. These characteristics make NM a potential alternative to conventional anticoagulation strategies, particularly for patients at high risk of bleeding. This study aimed to systematically evaluate the efficacy and safety of NM as an anticoagulant for ECMO\/CRRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang Data were systematically searched for randomized controlled trials and cohort studies comparing NM with sodium citrate, unfractionated heparin (UFH), or no anticoagulation. A meta-analysis was conducted to evaluate filter lifespan, bleeding events, thromboembolic events, and 28-day\/intensive care unit (ICU) mortality. Reporting characteristics and potential safety signals for the three anticoagulants were also compared using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The meta-analysis included 17 studies involving 1,893 patients. Filter lifespan did not differ significantly between the NM and control groups (mean difference [MD] = 1.29 h; 95% confidence interval [CI], \u22121.09\u20133.66), whereas the risk of bleeding events was significantly lower in the NM group (odds ratio [OR] = 0.61; 95% CI, 0.43\u20130.86). Subgroup analyses showed that NM was associated with a significantly lower risk of bleeding than sodium citrate (OR = 0.53; 95% CI, 0.31\u20130.90) and no anticoagulation (OR = 0.41; 95% CI, 0.19\u20130.90); sensitivity analyses supported the robustness of this finding. The FAERS analysis included 24,238 reports, comprising 233 for NM, 1,612 for sodium citrate, and 22,393 for UFH, with distinct reporting profiles observed among the three anticoagulants. Representative signals for NM included disseminated intravascular coagulation (n = 17; ROR = 112.68, 95% CI: 69.69\u2013182.19), gastrointestinal hemorrhage (n = 12; ROR = 15.44, 95% CI: 8.74\u201327.29), and decreased platelet count (n = 13; ROR = 7.52, 95% CI: 4.35\u201313.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NM may reduce bleeding risk while maintaining a filter lifespan comparable to that achieved with other anticoagulation strategies, potentially providing an individualized anticoagulation option for patients at high risk of bleeding. In clinical practice, coagulation abnormalities, changes in platelet counts, and bleeding-related events should be closely monitored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1922982","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:43:45Z","timestamp":1790833425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of nafamostat mesilate for anticoagulation during ECMO\/CRRT: insight from the integrated meta-analysis and FAERS pharmacovigilance study"],"prefix":"10.3389","volume":"17","author":[{"given":"Gaojin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Provincial Clinical College of Fujian Medical University \/ Fujian Provincial Hospital \/ Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]},{"name":"The School of Pharmacy, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delian","family":"Zhong","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Fujian University of Traditional Chinese Medicine","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Provincial Clinical College of Fujian Medical University \/ Fujian Provincial Hospital \/ Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]},{"name":"The School of Pharmacy, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjie","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Provincial Clinical College of Fujian Medical University \/ Fujian Provincial Hospital \/ Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]},{"name":"The School of Pharmacy, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Provincial Clinical College of Fujian Medical University \/ Fujian Provincial Hospital \/ Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Provincial Clinical College of Fujian Medical University \/ Fujian Provincial Hospital \/ Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/0886022x.2011.647293","article-title":"The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding","volume":"34","author":"Baek","year":"2012","journal-title":"Ren. Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B3","first-page":"89","article-title":"Comparison of anticoagulant efficacy and safety between nafamostat mesylate and citrate in high-bleeding-risk patients undergoing CRRT","volume":"8","author":"Chen","year":"2024","journal-title":"J. Pract. Shock"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2392","DOI":"10.1097\/md.0000000000002392","article-title":"Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial","volume":"94","author":"Choi","year":"2015","journal-title":"Med. Baltim."},{"key":"B5","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1442065","DOI":"10.3389\/fmed.2024.1442065","article-title":"How to safeguard the continuous renal replacement therapy circuit: a narrative review","volume":"11","author":"Hu","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5301\/ijao.5000191","article-title":"Nafamostat mesilate for anticoagulation in continuous renal replacement therapy","volume":"36","author":"Hwang","year":"2013","journal-title":"Int. J. Artif. Organs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.13201\/j.issn.1009-5918.2025.10.007","article-title":"Comparison of anticoagulant effects of nafamostat mesilate and sodium citrate in continuous renal replacement therapy for patients with acute kidney injury","volume":"26","author":"Jiang","year":"2025","journal-title":"J. Clin. Emerg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.20116\/j.issn2095-0616.2025.17.17","article-title":"Observation of the anticoagulant efficacy of nafamostat mesylate in continuous renal replacement therapy","volume":"15","author":"Jiang","year":"2025","journal-title":"China Med. Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12882-023-03060-1","article-title":"Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study","volume":"24","author":"Kameda","year":"2023","journal-title":"BMC Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.23876\/j.krcp.23.310","article-title":"The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety","volume":"43","author":"Kim","year":"2024","journal-title":"Kidney Res. Clin. Pract."},{"key":"B13","first-page":"1432","article-title":"Application effect of injectable nafamostat mesylate in CRRT treatment for acute kidney injury","volume":"29","author":"Lan","year":"2024","journal-title":"Zhejiang J. Trauma. Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","article-title":"Anticoagulation with nafamostat mesilate during extracorporeal life support","volume":"366","author":"Lang","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e108737","DOI":"10.1371\/journal.pone.0108737","article-title":"Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate Versus heparin","volume":"102","author":"Lim","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/0886022x.2022.2105233","article-title":"Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis","volume":"44","author":"Lin","year":"2022","journal-title":"Ren. Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","article-title":"Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study","volume":"29","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-025-05813-w","article-title":"Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis","volume":"30","author":"Liu","year":"2025","journal-title":"Crit. Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5301\/ijao.5000465","article-title":"Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy","volume":"39","author":"Makino","year":"2016","journal-title":"Int. J. Artif. Organs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/cid\/ciae120","article-title":"Nosocomial infections in adults receiving extracorporeal membrane oxygenation: a review for infectious diseases clinicians","volume":"79","author":"Marcus","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100283","DOI":"10.1016\/j.rpth.2023.100283","article-title":"Heparin-induced thrombocytopenia: an illustrated review","volume":"7","author":"May","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3969\/j.issn.2095-7165.2025.05.010","article-title":"Comparison of the application effects of nafamostat mesilate and sodium citrate anticoagulation in CRRT in patients with chronic renal failure with high bleeding risk","volume":"15","author":"Niu","year":"2025","journal-title":"Dr. Online"},{"key":"B24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/ndt\/7.9.980a","article-title":"Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostat mesilate","volume":"7","author":"Okada","year":"1992","journal-title":"Nephrol. Dial. Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s44158-023-00091-w","article-title":"Regional citrate anticoagulation (RCA) in critically ill patients undergoing renal replacement therapy (RRT): expert opinion from the SIAARTI-SIN joint commission","volume":"3","author":"Pistolesi","year":"2023","journal-title":"J. Anesth. Analg. Crit. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12882-025-04272-3","article-title":"Infections and mortality in ICU patients undergoing continuous renal replacement therapy: a retrospective cohort study","volume":"26","author":"Quickfall","year":"2025","journal-title":"BMC Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"727717","DOI":"10.3389\/fphar.2021.727717","article-title":"Drug-induced idiosyncratic agranulocytosis - infrequent but dangerous","volume":"12","author":"Rattay","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.xkme.2023.100641","article-title":"Epidemiology and outcomes of AKI treated with continuous kidney replacement therapy: the multicenter CRRTnet study","volume":"5","author":"Rewa","year":"2023","journal-title":"Kidney Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.3390\/jcm12206618","article-title":"RAndomized clinical trial of NAfamostat mesylate, A potent transmembrane protease serine 2 (TMPRSS2) inhibitor, in patients with COVID-19 pneumonia","volume":"12","author":"Seccia","year":"2023","journal-title":"J. Clin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e44932","DOI":"10.1097\/md.0000000000044932","article-title":"Efficacy and safety of naphlimostat mesylate versus sodium citrate in CRRT for EICU patients with coagulation dysfunction: a STROBE-compliant observational study","volume":"104","author":"Song","year":"2025","journal-title":"Med. Baltim."},{"key":"B34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/03913988251360552","article-title":"Different anticoagulation methods for continuous renal replacement therapy in patients with hyperlactataemia and a high risk of bleeding","volume":"48","author":"Song","year":"2025","journal-title":"Int. J. Artif. Organs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.19368\/j.cnki.2096-1782.2024.15.091","article-title":"Analysis of the anticoagulant effect of nafamostat mesylate in blood purification patients at high risk of bleeding","volume":"9","author":"Sun","year":"2024","journal-title":"Syst. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ijid.2020.10.093","article-title":"Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation","volume":"102","author":"Takahashi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/mat.0000000000002128","article-title":"Extracorporeal life support organization registry international report 2022: 100,000 survivors","volume":"70","author":"Tonna","year":"2024","journal-title":"Asaio J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2020.18618","article-title":"Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial","volume":"324","author":"Zarbock","year":"2020","journal-title":"Jama"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2580058","DOI":"10.1080\/0886022x.2025.2580058","article-title":"Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety","volume":"47","author":"Zeng","year":"2025","journal-title":"Ren. Fail"},{"key":"B41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.52547\/5j9v7385","article-title":"Effects of nafamostat mesilate and systemic unfractionated heparin anticoagulation on coagulation, renal function, and 28-day survival status in critically ill AKI CRRT patients","volume":"19","author":"Zhan","year":"2025","journal-title":"Iran. Journal Kidney Diseases"},{"key":"B42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.12007\/j.issn.0258-4646.2025.07.016","article-title":"Comparison of anticoagulant effects of nafamostat mesylate and sodium citrate in continuous renal replacement therapy","volume":"54","author":"Zhang","year":"2025","journal-title":"J. China Med. Univ."},{"key":"B43","first-page":"393","article-title":"Anticoagulant effect and safety of nafamostat mesylate in continuous blood purification","volume":"44","author":"Zhang","year":"2024","journal-title":"Int. J. Urology Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41598-025-88838-z","article-title":"Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.13683\/j.wph.2022.09.011","article-title":"Application of nafamostat mesylate anticoagulation in continuous renal replacement therapy for patients with high bleeding risk after cardiovascular surgery","volume":"43","author":"Zhou","year":"2022","journal-title":"World Clin. Drugs"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1922982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:43:51Z","timestamp":1790833431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1922982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":45,"alternative-id":["10.3389\/fphar.2026.1922982"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1922982","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1922982"}}